Arvinas to Present at Upcoming Investor Conferences
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, will participate in two virtual investor conferences in February 2022. The first is the Guggenheim Oncology Conference on February 10, featuring Chief Scientific Officer Ian Taylor. The second is the 2022 SVB Leerink Global Healthcare Conference on February 18, with insights from President and CEO John Houston. Live webcasts of both presentations will be accessible on the company's website.
Arvinas aims to revolutionize treatments for serious diseases through innovative therapies targeting disease-causing proteins.
- None.
- None.
NEW HAVEN, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences:
Guggenheim Oncology Conference on Thursday, February 10. Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.
2022 SVB Leerink Global Healthcare Conference on Friday, February 18. John Houston, Ph.D., President and Chief Executive Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.
About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has three clinical-stage programs: ARV-110 and ARV-766 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.
Investor Contact:
Jeff Boyle
(347) 247-5089
jeff.boyle@arvinas.com
Media Contact:
Kirsten Owens
(203) 584-0307
kirsten.owens@arvinas.com
FAQ
What are the upcoming investor conferences for Arvinas in February 2022?
Who will represent Arvinas at the Guggenheim Oncology Conference?
Who will speak for Arvinas at the 2022 SVB Leerink Global Healthcare Conference?
Where can I find the live webcasts for Arvinas' conference presentations?
What is the focus of Arvinas' research?
